Pharmafile Logo
Pharmafocus logo
Advanced Search

Vertex

Showing 15 posts of 40 posts found.

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

February 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, England, NHS, Purdue, Vertex, insys, israel, oncology, pharma, top 10

Scandal dominated this week’s news after Sunrise Lee, a stripper turned Insys sales rep was alleged to have given a …

News
vertex-headquarters

Vertex ousts COO Ian Smith over ‘personal behaviour’

January 24, 2019
Business Services Ian Smith, Jobs, Vertex, executives

Boston-based firm Vertex Pharmaceuticals has fired Chief Operating Officer (COO) and interim Chief Financial Officer (CFO) Ian Smith. Smith’s termination, …

News
vertex-headquarters

Vertex’s Orkambi can be used in even younger cystic fibrosis patients, says European Commission

January 22, 2019
Manufacturing and Production, Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma

Vertex has announced that the European Commission has decided to approve a label extension in the region for Orkambi (lumacaftor/ivacaftor) …

News
14680814113_e81affc144_z_1

UK Health Secretary Matt Hancock rallies against ‘rip off’ pharma companies

September 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Matt Hancock, NICE, Vertex, pharma, pricing

British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …

News
si_lem_new_photo_171118

Working Life: Vertex Pharma’s Simon Lem, VP, Regional General Manager of North Europe

June 25, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, Vertex pahrma, Working Life, feature, pharma

Pharmafocus caught up with Vertex Pharma’s Simon Lem to discuss his journey throughout the industry and the importance of the …

Feature
houses-of-parliament-1055056_960_720

UK Ministers call on Vertex to speed up price negotiations

April 23, 2018
Sales and Marketing NHS, NICE, Orkambi, UK government, Vertex, biotech, drugs, pharma, pharmaceutical

After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …

News
cystic_fibrosis_insider_interview

Transforming cystic fibrosis treatment

April 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …

Feature
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Celgene, Lundbeck, Marijuana, Novartis, Roche, Vertex, brexit, cannabis, multiple sclerosis, neuroscience, pharma

As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …

News
upper-body-944557_960_720

Vertex “astonished” by NHS England’s response to CF drug

March 20, 2018
Manufacturing and Production, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Vertex has been battling to have its treatment, Orkambi, approved in the UK since 2016, when it was first rejected …

News
cell-3089947_960_720

Vertex gets approval for combo-therapy in cystic fibrosis

February 13, 2018
Manufacturing and Production, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

All eyes are on Vertex’s two Phase 3 trials into a triple therapy for cystic fibrosis (CF), in the meantime, …

News
mr058666-web

Merck in $230 million swoop for Vertex cancer programmes

January 16, 2017
Sales and Marketing Vertex

Merck has completed a deal with Boston-based biotech firm Vertex Pharmaceuticals for the rights to four cancer programmes worth $230 …

News
kalydeco

Vertex stumbles in Phase III cystic fibrosis trials

August 16, 2016
Manufacturing and Production, Research and Development Vertex, cystic fibrosis, phase III

Vertex Pharmaceuticals has provided an update on its ongoing Phase III trials investigating VX-661 in combination with Kalydeco (ivacaftor) in …

News
shutterstock_87495637

Orkambi deemed not suitable for NHS use

July 27, 2016
Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis

The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …

News
nice

NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi

March 23, 2016
Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis

NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …

News
Vertex logo

Vertex’s cystic fibrosis drug gets FDA approval

July 3, 2015
Research and Development, Sales and Marketing FDA, Orkambi, Vertex, cystic fibrosis, gene therapy

Vertex Pharmaceuticals cystic-fibrosis drug Orkambi, which could treat as many as 8,500 patients in the US, has been approved by …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026